Expasy logo

UniProtKB/Swiss-Prot variant pages

UniProtKB/Swiss-Prot Q14654: Variant p.Phe60Tyr

ATP-sensitive inward rectifier potassium channel 11
Gene: KCNJ11
Feedback?
Variant information Variant position: help 60 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Type of variant: help LP/P [Disclaimer] The variants are classified into three categories: LP/P, LB/B and US.
  • LP/P: likely pathogenic or pathogenic.
  • LB/B: likely benign or benign.
  • US: uncertain significance
Residue change: help From Phenylalanine (F) to Tyrosine (Y) at position 60 (F60Y, p.Phe60Tyr). Indicates the amino acid change of the variant. The one-letter and three-letter codes for amino acids used in UniProtKB/Swiss-Prot are those adopted by the commission on Biochemical Nomenclature of the IUPAC-IUB.
Physico-chemical properties: help Similar physico-chemical property. Both residues are large size and aromatic. The physico-chemical property of the reference and variant residues and the change implicated.
BLOSUM score: help 3 The score within a Blosum matrix for the corresponding wild-type to variant amino acid change. The log-odds score measures the logarithm for the ratio of the likelihood of two amino acids appearing by chance. The Blosum62 substitution matrix is used. This substitution matrix contains scores for all possible exchanges of one amino acid with another:
  • Lowest score: -4 (low probability of substitution).
  • Highest score: 11 (high probability of substitution).
More information can be found on the following page
Variant description: help In PNDM2; the patient also carries L-64 in cis; displays gain of function; increases the intrinsic channel open probability and decreases sensitivity toward ATP inhibition; variant L-64 associated in cis is thought to ameliorate the effect of the Y-60 mutation on the channel ATP sensitivity. Any additional useful information about the variant.
Other resources: help Links to websites of interest for the variant.


Sequence information Variant position: help 60 The position of the amino-acid change on the UniProtKB canonical protein sequence.
Protein sequence length: help 390 The length of the canonical sequence.
Location on the sequence: help GNCNVAHKNIREQGRFLQDV F TTLVDLKWPHTLLIFTMSFL The residue change on the sequence. Unless the variant is located at the beginning or at the end of the protein sequence, both residues upstream (20) and downstream (20) of the variant will be shown.
Residue conservation: help The multiple alignment of the region surrounding the variant against various orthologous sequences. 
Human                         GNCNVAHKNIREQGRFLQDVFTTLVDLKWPHTLLIFTMSFL

Mouse                         GNCNVAHKNIREQGRFLQDVFTTLVDLKWPHTLLIFTMSFL

Rat                           GNCNVAHKNIREQGRFLQDVFTTLVDLKWPHTLLIFTMSFL

Rabbit                        GNCNVAHKNIREQGRFLQDVFTTLVDLKWTHTLLIFTMSFL
Sequence annotation in neighborhood: help The regions or sites of interest surrounding the variant. In general the features listed are posttranslational modifications, binding sites, enzyme active sites, local secondary structure or other characteristics reported in the cited references. The "Sequence annotation in neighborhood" lines have a fixed format:
  • Type: the type of sequence feature.
  • Positions: endpoints of the sequence feature.
  • Description: contains additional information about the feature.
TypePositionsDescription
Chain 1 – 390 ATP-sensitive inward rectifier potassium channel 11
Topological domain 1 – 68 Cytoplasmic
Alternative sequence 1 – 87 Missing. In isoform 2.
Mutagenesis 64 – 64 V -> M. Displays gain of function; increased open state stability, reduced ATP sensitivity and increased channel activity; almost completely abolishes high affinity sensitivity to glibenclamide, an inhibitor of ATP-sensitive potassium channels.
Helix 59 – 64



Literature citations
Interaction between mutations in the slide helix of Kir6.2 associated with neonatal diabetes and neurological symptoms.
Maennikkoe R.; Jefferies C.; Flanagan S.E.; Hattersley A.; Ellard S.; Ashcroft F.M.;
Hum. Mol. Genet. 19:963-972(2010)
Cited for: INVOLVEMENT IN PNDM2; VARIANTS PNDM2 TYR-60 AND LEU-64; CHARACTERIZATION OF VARIANTS PNDM2 TYR-60 AND LEU-64;
Disclaimer: Any medical or genetic information present in this entry is provided for research, educational and informational purposes only. They are not in any way intended to be used as a substitute for professional medical advice, diagnostic, treatment or care.